Drugs / PF-00610355
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01107054 | Jun → Sep 2010 | lung disorder | Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00808288 | Mar → Dec 2010 | chronic obstructive pulmonary disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00830427 | Apr → Dec 2009 | asthma, obstructive lung disease | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00783406 | Oct 2008 → Mar 2009 | chronic obstructive pulmonary disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00468975 | May 2007 → ? | asthma | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF - 00610355 | “Drug: PF - 00610355” NCT00830427 ↗ |
| Known as | PF-610,355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00468975 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL1240967 ↗ |
| Modality | Small molecule | — CHEMBL1240967 ↗ |
| Route | Inhaled | “dry powder inhaler, 1472 mcg, single dose” NCT00783406 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL1240967 ↗ |